Transformation of the Ukrainian pharmaceutical market – new opportunities and potential Pharmaceutical Industry Review, September No 4 (97) 2023
5 minutes with... Klym Tymko, Executive Director of Microkhim, LLC
During the war, many companies managed to maintain their positions not only in the domestic market but also in foreign markets. Some have discovered new opportunities. In what direction is your company moving?
Over the past year, we have been working on changing our business model and setting up internal processes related to this, as we have lost our own production. It was a real challenge for us because for 30 years the company had been operating at its own facilities and positioned itself
as a production company. I am sure that we should be proud of how resilient we have proved to be, and despite all the obstacles, we have retained our team, preserved our portfolio of products and continued to develop our expertise. Despite all the difficulties, in 2022 we were able to successfully launch the only domestic thiocolchicoside in injectable form. We also have 6 more launches planned in the near future. We have lost our own production, but we have very strong expertise in R&D, focusing on innovative approaches and unique forms. This is our focus now. Thanks to our partners, we were able to set up all the processes and resume production of our portfolio quickly enough, amidst the war and uncertainty.
Today, experts are talking about changing trends in the Ukrainian
INFORMATION ON THE COMPANY
Microkhim, LLC, a Ukrainian pharmaceutical company, develops, researches and sells high-quality, modern medicines and implements original ideas in pharmaceuticals. The company is manufacturing products for application in cardiology, neurology, gastroenterology, orthopedics and surgery.
Microkhim, LLC has been operating in the Ukrainian pharmaceutical market for more than 30 years and was always been distinguished for its cutting-edge developments, although the company's scale and R&D budget are significantly lower than those of leading pharmaceutical manufacturers.
Microkhim, LLC became the No. 1 producer of nitrates in Ukraine, launched the first domestic isosorbide dinitrate and nitroglycerin spray medicines, registered the first domestic drug for the treatment of pulmonary arterial hypertension, and in 2020 became the leader in the number of bioequivalence studies in Ukraine. Microkhim, LLC also has its own unique combinations in the cardiology portfolio, which were the first to be produced in Ukraine – the most complete line of drugs based on perindopril and valsartan, including triple combinations.
The company existed and operated at its own facilities in Rubizhne, Luhansk region, but after the city was occupied and its infrastructure destroyed, Microkhim, LLC was forced to refocus on contract manufacturing and entered into partnerships with leading domestic pharmaceutical manufacturers.
26
BACK TO CONTENTS
www.promoboz.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
